Home/Pipeline/Glaucoma Portfolio

Glaucoma Portfolio

Glaucoma

CommercialActive

Key Facts

Indication

Glaucoma

Phase

Commercial

Status

Active

Company

Visufarma

About Visufarma

Visufarma is a commercial-stage ophthalmic company formed in 2016 from the combination of Italy's Visufarma SpA and the commercial activities of France's Nicox SA. The company markets an established portfolio of products for dry eye, glaucoma, eyelid hygiene, and retinal health supplements, positioning itself as a specialized player in the European eye care market. Its strategy centers on commercializing innovative products sourced globally, supported by a focus on customer service and professional education. Visufarma is a private company with ambitions to become a recognized partner of choice in eye health across Europe and beyond.

View full company profile

Therapeutic Areas

Ophthalmology Dry Eye Disease Glaucoma Ocular Allergy Blepharitis Retinal Health

Other Glaucoma Drugs

Drug	Company	Phase	Status
PREZIA Glaucoma Implant	PolyActiva	Preclinical	Active
MIGS Device System	Micropoint Biotechnologies	Commercial	Market approved in China
INM-088	InMed Pharmaceuticals	Preclinical	Active
OT-401	Ocumension Therapeutics	Phase 2	Active
ANX007	Annexon Biosciences	Phase 2	Active
PER-001	Perfuse Therapeutics	Phase 2	Active
hOTX2	BrainEver	Discovery	Active
Glaucoma Treatment	BVI Medical	Commercial	Active
MediPrint Lens (Glaucoma)	MediPrint Ophthalmics	Phase 2b	Active
Glaucoma Program	Broadwing Bio	Pre-clinical	Active
MSC Exosomal Eye Serum	Vitti Labs	Pre-clinical	Active
BTQ1902	Betaliq	Phase 2	Active